Chitomed Establishes New Headquarters in the Netherlands to Advance Biomaterials R&D and Manufacturing
The company will harness Dutch innovation and collaboration to catalyze medical technology breakthroughs for global impact
Chitomed B.V., a company focused on the research and implementation of advanced medical technologies, has established its headquarters in the Netherlands. The company is set to advance chitosan-based medical devices in the pharmaceutical, medical and cosmetics industries while tapping into the connected life sciences and health ecosystem in the Netherlands.
Chitomed has opened an office at the Medace facility in Maastricht, a co-workspace for biomedical companies.
“Our decision to relocate to the Netherlands is driven by our strategic vision for global impact,” said Edyta Wątrobińska, Polish founder and managing director of Chitomed. “We are impressed by the country’s culture of cooperation between organizations, the synchronization of activities, the competence of human resources, the infrastructure and business environment, and above all the openness of investors to the medical biotechnology industry. The Netherlands provides an ideal environment for Chitomed to thrive, and we look forward to contributing significantly to the country’s dynamic business landscape.”
Finding fertile ground in the Netherlands
Harnessing the Dutch “quadruple helix” approach, where government, business, academia and society collaborate to find solutions for the future, the Netherlands was the ideal choice for the company’s new global headquarters. Already a member of the Smart BioMaterials Consortium (SBMC) based in Eindhoven, Chitomed also started collaborations with universities and clinics in the region such as Maastricht University Medical Center+.
“We believe in synergy when working together; this is a recipe for success in a market as competitive as medical. The Dutch Life Sciences and Health ecosystem has given us the opportunity to develop such cooperation,” added Wątrobińska. “We already feel a part of the Dutch ecosystem of support for medical innovation.”
Now a part of the Dutch ecosystem of medical innovation, Chitomed is poised for further growth and collaboration within the country’s thriving regenerative medicine community. As the company integrates into the Dutch innovation landscape, its expansion is a testament to the Netherlands as a global hub for cutting-edge medical advancements.
Biomaterials driving the future of medical treatment from the Netherlands
Chitomed’s innovative technologies and medical devices are advancing global health. The polymer chitosan, known for its multifunctional properties in tissue regeneration and unique biocidal characteristics, has long been recognized for its potential in the medical field. The company’s interdisciplinary approach, combining the expertise of engineers and doctors, aims to develop solutions that directly respond to the needs of healthcare professionals. Upon their visit to the Netherlands, Chitomed’s team discovered that the country is a leading center of expertise for chitosan, offering high-quality production infrastructure and proximity to potential partners.
Support from Invest in Holland Network
Chitomed worked closely with the Netherlands Foreign Investment Agency and Invest in Holland partner LIOF when looking for the best location to establish its business operations. Upon making the decision to set up its headquarters in Maastricht, the company continued to draw upon the support of NFIA and LIOF.
About Chitomed
Chitomed spearheads the development and implementation of groundbreaking technological solutions for the pharmaceutical, medical and cosmetics industries. Specializing in chitosan and microcrystalline chitosan, they are at the forefront of innovation. Collaborating with accomplished scientists who bring years of detailed study in chitosan and its processing technologies, Chitomed is driven by their commitment to excellence. They are shaping the future of industries, merging science and technology to create unparalleled possibilities.
Source: Chitomed
1 February 2024